

COPY OF PAPERS
ORIGINALLY FILED

#6


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	E. De Robertis	Examiner:	Not Yet Assigned
Serial No.	09/903,188	Group Art Unit:	1647
Filed:	July 11, 2001	Docket No.	510015-258
Title:	ENDODERM, CARDIAC, AND NEURAL INDUCING FACTORS— HUMAN FRAZZLED (FRZB-1) PROTEIN		

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 21, 2002.


Kelly Walsh

COMMUNICATION AND TRANSMITTAL OF CORRECTED SEQUENCE LISTING

Honorable Commissioner for Patents
Washington, D.C. 20231

Gentlemen:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed January 8, 2002, Applicants submit a corrected Sequence Listing. On reviewing the specification of the above-identified patent application, Applicants have noted that the sequences listed in the paper and machine-readable copy of the Sequence Listing previously submitted are not identical to the sequences recited in the specification and figures as originally filed with the Patent and Trademark Office. Specifically, errors exist in SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 10 of the sequences listed in the paper and machine-readable copy of the Sequence Listing; these sequences are not identical with those recited in the specification and figures of the originally-filed application. In order to correct this error, Applicants hereby submit a corrected Sequence Listing.


This corrected Sequence Listing is presented in a computer readable form and in a paper copy. The content of the paper and computer readable copies is the same. The corrected Sequence Listing includes no new matter, as the sequences themselves have not changed from their recitation in the specification and in the drawings. Specifically, the sequences in the Sequence Listing are identical to SEQ ID NO: 1-10 as shown in Figures 1-10 of the application as originally filed. There is therefore support for the sequences recited in this corrected Sequence Listing in the application as originally filed. This corrected sequence listing complies with the requirements of 37 C.F.R. §1.825(a) and §1.825(b), and is believed to place the application in compliance with 37 C.F.R. §§ 1.821-1.825.

A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed with this transmittal.

If any further changes or corrections are required, the Examiner is respectfully requested to telephone the undersigned at (310) 788-5098.

Date: February 21, 2002

Respectfully submitted,



Charles Berman
Reg. No. 29,249

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East
38th Floor
Los Angeles, CA 90067-3024
Phone: (310) 788-5098
FAX: (310) 788-5100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DeRobertis et al.

Examiner: Unknown

Serial No.: 09/903,188

Group Art Unit: 1647

Filed: July 11, 2001

Docket: 510015-258

Due Date: March 15, 2002

Title: ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - HUMAN FRAZZLED (FRZB-1) PROTEIN

COPY OF PAPERS
ORIGINALLY FILED



CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 21, 2002.

Kelly Walsh

Assistant Commissioner for Patents

Box: Missing Parts

Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Communication and Transmittal of Corrected Sequence Listing
- ☒ Sequence Listing in computer readable and paper form
- ☒ Copy of Notice to Comply
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230. A duplicate of this sheet is enclosed.

OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, 38th Floor

Los Angeles, CA 90067-3024

(310) 788-5000

Email: CBerman@oppenheimer.com

By:

Name: Charles Berman

Reg. No.: 29,249

CB:kw



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPERS
ORIGINALLY FILEDCOMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/903,188	07/11/2001	Edward M. De Robertis	510015-258

Attention : Charles Berman
 OPPENHEIMER WOLFF & DONNELLY
 38th Floor
 2029 Century Park east
 Los Angeles, CA 90067-3024



CONFIRMATION NO. 1059

FORMALITIES LETTER



OC000000007311905

6/c

Date Mailed: 01/15/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE